Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell

Figure 1 Inhibition of gelatinase activity of LS174T cell by docetaxel. After treated with 0.1, 0.2, 0.5, 1.0 ng/mL concentration of docetaxel, the activity of MMP2 AND 9 was inhibited. Representative results from three independent experiments: Con. docetaxel solvent control group; 1-3: 0.1, 0.5, 1.0 ng/mL concentrations of docetaxel.

Figure 2 Inhibition of expression of proteins of LS174T cell by docetaxel. After treated with 0.1, 0.2, 0.5, 1.0 ng/mL concentration of docetaxel, the level of VEGF, bFGF, MMP2, MMP9 protein of LS174T cell was inhibited by docetaxel respectively. Represen-tative results from three independent experiments. a. b. c. d. VEGF, bFGF, MMP2, MMP9 proteins (M_r. was 22000, 18000, 72000 and 92000) of LS174T cell; Con: Docetaxel solvent con-trol group, 1-3: 0.1, 0.5, 1.0 ng/mL concentrations of docetaxel.

Figure 3 Inhibition of expression of mRNA of LS174T cell by docetaxel. After treated with 0.1, 0.2, 0.5, 1.0 ng/mL concen-tration of docetaxel, the level of VEGF, bFGF, MMP2, MMP9 protein of LS174T cell was inhibited by docetaxel respectively. Representative results from three independent experiments. a. b. c. d. e. VEGF, bFGF, MMP2, MMP9 mRNA and GAPDH (210 bp, 734 bp, 426 bp, 659 bp and 310 bp, 500 bp). Con: docetaxel solvent control group, a. b. c. d; 1-3: 0.1, 0.5, 1.0 ng/mL concentrations of docetaxel. M: marker, e; 1-4: Internal control groups.